Anteris Technologies Global Corp. — Board/Management Information 2016

Feb 8, 2016

Admedus Ltd ABN 35 088 221 078

REGISTERED OFFICE: 26 Harris Road Malaga Western Australia 6090

==> picture [226 x 82] intentionally omitted <==

ASX ANNOUNCEMENT

PO Box 6879 East Perth Western Australia 6892 T +61 (0)8 9266 0100 F +61 (0)8 9266 0199 E info.au@admedus.com

www.admedus.com

ADMEDUS APPOINTS NEW CHAIRMAN

• Mr Wayne Paterson appointed new Admedus Chairman following the resignation of Mr Chris Catlow and Director Mr Graeme Rowley

• Collective expertise of the current board fully aligned with Admedus’ medtech and biotech focus

Brisbane, Australia 9 February 2016

Admedus Limited (ASX: AHZ) has today announced that the Board has appointed Mr Wayne Paterson as Non-Executive Chairman with immediate effect. This follows the resignation of Mr Chris Catlow who held that position for 5 years. Mr Graeme Rowley, who served as a non-executive Director for 5 years, has also resigned. Messrs Catlow and Rowley have also been involved with the Group for the past 11 years holding non-executive director positions for subsidiary companies.

“The Board and I would like to thank Chris and Graeme for their work in establishing Admedus and their help in growing it into the diversified healthcare company it is today. Their contributions have been invaluable over the years”, said incoming Chair Wayne Paterson. “The board now looks forward to applying our collective energies to the next chapter of Admedus’ development and further improving patient outcomes and as a result shareholder value”.

CEO Lee Rodne commented that, “the Admedus board now consists of directors with extensive experience in each of our core product areas with specific backgrounds in sales, marketing, general management and corporate governance. We look forward to their ongoing input to our outstanding management team.”

Mr Paterson joined the Admedus board in 2015 having spent 25 years in the Global Pharmaceutical industry managing diverse and complex global operations at Roche and Merck. Over his career he has been responsible for substantial revenues and operations and held the positions of President Europe, Canada and Australia, President of Emerging markets, President of Japan, Global head of Cardiovascular and general medicine amongst others. Mr Paterson is also a Non-Executive Director of a NASDAQ listed molecular diagnostics company.

Biographical information on all directors can be found on the Company’s website at www.Admedus.com

==> picture [595 x 44] intentionally omitted <==

==> picture [170 x 63] intentionally omitted <==

Follow us: Twitter: @Admedus Facebook: www.facebook.com/pages/Admedus

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100

Media :

Shevaun Cooper | PR Manager | Admedus Limited Tel: +61 (0) 417 985 599 | Email: scooper@admedus.com

Media Europe

FTI Consulting Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000 admedus@fticonsulting.com

US Investor

Rx Communications Group, LLC Melody A. Carey +1 917 322 2571 mcarey@rxir.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com